Prolonged survival with increasing duration of lenalidomide maintenance after autologous transplant for multiple myeloma

Isabel G. Amsler(University Hospital of Bern), Thomas Pabst(University Hospital of Bern), Thilo Zander(Luzerner Kantonsspital), Ulrike Bacher(Hattiesburg Clinic), Urban Novak(University of Bern), Jean-Marc Luethi(University Hospital of Bern), Thomas Egger(Solothurner Spitäler), Daniel Betticher, Behrouz Mansouri Taleghani(University of Bern), Barbara Jeker(University of Bern)
Leukemia & lymphoma/Leukemia and lymphoma
January 8, 2019
10.1080/10428194.2018.1473577
Cited by 15

Related Papers

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2019|3.4k
Prognostic relevance of FLT3-TKD mutations in AML: the combination matters—an analysis of 3082 patients
|Blood|2007|410
Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial
|The Lancet|2015|392
Prognostic significance of CCND1 (cyclin D1) overexpression in primary resected non-small-cell lung cancer
|British Journal of Cancer|1996|220
Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome
|Blood|2010|189